RBC Capital upgraded Sage Therapeutics (SAGE) to Sector Perform from Underperform with an unchanged price target of $4. The firm says that this morning’s announced failure of dalzamendor in Huntington’s disease and discontinuation of the program, its thesis on potential stock downside into and through the data readout has played out. The end of the road for dalzamendor means Sage will now have to work through a strategic reset while launching Zurzuvae, the analyst tells investors in a research note. As the company sorts out next steps for its share of Zurzuvae and earlier stage pipeline, RBC expects the shares to trade more in line.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
- Sage Therapeutics reported another clinical setback, says H.C. Wainwright
- Sage Therapeutics reports results from Phase 2 DIMENSION Study
- Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
- Sage Therapeutics price target lowered to $9 from $11 at Morgan Stanley